Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment
Authors:
Open Access
- 2 July 2025
- journal article
- review article
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-13
Abstract
Immune-checkpoint targeting Drug Conjugates (IDCs) are a novel class of therapeutics that combine an immune checkpoint-targeting moiety, a cleavable linker, and a cytotoxic payload. By integrating features and functions of antibody-drug conjugates and immunotherapy, IDCs represent a promising strategy to remodel the tumor microenvironment and enhance antitumor efficacy. Several IDCs targeting checkpoints such as PD-L1, B7-H3, and B7-H4 are in early-phase clinical trials. This review summarizes available data on IDC efficacy and toxicity in human. Although current evidence is limited, ongoing phase III trials and biomarker studies will clarify their optimal clinical role, including potential for tumor-agnostic use.Keywords
This publication has 52 references indexed in Scilit:
- 690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II studyAnnals of Oncology, 2023
- 660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)Annals of Oncology, 2023
- 381O First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumorsAnnals of Oncology, 2023
- 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansionAnnals of Oncology, 2021
- Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapyJournal of Cellular Physiology, 2019
- First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinomaCancer Chemotherapy and Pharmacology, 2019
- Antibody-drug conjugates: recent advances in conjugation and linker chemistriesProtein & Cell, 2016
- Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumorsInvestigational New Drugs, 2016
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70Cancer Chemotherapy and Pharmacology, 2015
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaInvestigational New Drugs, 2014